Nicholas Mellis
Internal Medicine · Timonium, MDNPI 1588663108
Payments from drug & device makers
Across 65 payments — averaging $14.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$209
- Novo Nordisk$136
- Boehringer Ingelheim$104
- Lilly USA, LLC$66
- Amgen$45
- Takeda Pharmaceuticals U.S.A., Inc.$42
- plus $340 from 17 others
What the payments were for
- Food & beverage$943100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 10 | $209 |
| Novo Nordisk | 14 | $136 |
| Boehringer Ingelheim | 6 | $104 |
| Lilly USA, LLC | 4 | $66 |
| Amgen | 3 | $45 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $42 |
| Hikma Pharmaceuticals USA | 3 | $40 |
| Bausch Health US, LLC | 2 | $36 |
| Antares Pharma, Inc. | 2 | $30 |
| Merck | 2 | $29 |
| AbbVie(2 entities) | 2 | $26 |
| Aytu Biopharma, Inc. | 2 | $24 |
| GSK | 1 | $19 |
| Astellas Pharma US Inc | 1 | $18 |
| Phadia US Inc. | 1 | $17 |
| Adlon Therapeutics L.p. | 1 | $15 |
| Ironwood Pharmaceuticals, Inc | 1 | $14 |
| Pfizer | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
| Sunovion Pharmaceuticals Inc. | 1 | $11 |
| Sebela Pharmaceuticals Inc. | 1 | $11 |
How this compares
$943 in reported general payments places this provider in the 70th percentile of 2,979 internal medicine providers in Maryland.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 44 | $68,877 |
| OzempicSemaglutide | 44 | $55,745 |
| EliquisApixaban | 37 | $43,167 |
| Tresiba Flextouch U-200Insulin Degludec | 20 | $30,391 |
| XareltoRivaroxaban | 18 | $28,770 |
| Repatha SureclickEvolocumab | 34 | $26,204 |
| JardianceEmpagliflozin | 25 | $25,910 |
| SynthroidLevothyroxine Sodium | 38 | $4,358 |
| Esomeprazole Magnesium | 52 | $3,476 |
| Rosuvastatin Calcium | 126 | $3,068 |
| PaxlovidNirmatrelvir/Ritonavir | 24 | $2,858 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 19 | $2,418 |
| ValacyclovirValacyclovir Hcl | 13 | $2,142 |
| Colchicine | 16 | $2,040 |
| Colestipol Hcl | 11 | $1,864 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $66 | $68,87744 claims |
| Novo NordiskOzempic | $136 | $55,74544 claims |
| PfizerEliquis, Paxlovid | $14 | $46,02561 claims |
| Boehringer IngelheimJardiance | $104 | $25,91025 claims |
| AbbVieSynthroid | $26 | $4,35838 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,979 internal medicine providers in Maryland.
Other internal medicine in Timonium
- Shishir KhetanRockville$52.1M
- Steven GellerElkridge$15.1M
- Mary HowellHagerstown$6.2M
- Kristen MarroneBaltimore$5.6M
- Jonathan CohenRockville$5M
- Andrea ApoloBethesda$4.8M
- Peta-Gay Jackson BoothBaltimore$3.6M
- Rahul PatelRockville$2.8M
- Mark YarchoanBaltimore$2.4M
- Marianne MannHighland$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.